| 2017-07-17 07:16:04|
LNTH 07:16 07/17 07/17/17
Lantheus initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Travis Steed started Lantheus Holdings with an Overweight rating and $22 price target. The company's leading product Definity, an ultrasound contrast agent used in echocardiograms to improve the clarity of the diagnostic image, is likely to experience double-digit growth over the long-term, the analyst contends.